US equities |
META $642.62 ▲+0.00% MU $877.55 ▲+0.00% TSLA $372.22 ▲+0.00% SPCX $147.49 ▲+0.00% SNDK $1,238.03 ▲+0.00% NVDA $210.96 ▲+0.00% NU $15.16 ▲+0.00% NBIS $158.74 ▲+0.00%
FinancialContent

Enanta Pharmaceuticals, Inc. - Common Stock (NQ:ENTA)

11.64 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Enanta Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13th International RSV Symposium
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
The Analyst Verdict: Enanta Pharma In The Eyes Of 4 Experts ↗
 
Via Benzinga
News headline image
Thursday's session: gap up and gap down stocks ↗
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Thursday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
News headline image
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharma Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) ↗
 
Via Benzinga
News headline image
4 Analysts Assess Enanta Pharma: What You Need To Know ↗
 
Via Benzinga
News headline image
Enanta Pharma Earnings Analysis: Q4 Recap ↗
 
Via Benzinga
News headline image
United Airlines To Rally More Than 20%? Here Are Top Analyst Forecasts For Monday ↗
 
Via Benzinga
News headline image
CrowdStrike To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV)
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharma Q4 Earnings Assessment ↗
 
Via Benzinga
News headline image
Insights into Enanta Pharma Q4 Earnings ↗
 
Via Benzinga
News headline image
Enanta Pharma: Q4 Earnings Insights ↗
 
Via Benzinga
News headline image
Earnings Breakdown: Enanta Pharma Q4 ↗
 
Via Benzinga
News headline image
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharma's Earnings Outlook ↗
 
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On Enanta Pharma Through 4 Analysts ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 25, 2024 ↗
 
Via Benzinga
News headline image
Enanta Pharmaceuticals Reports Antiviral For Respiratory Syncytial Virus Reduces Virus Levels, Symptoms In Study ↗
Enanta Pharmaceuticals' EDP-323 shows promising Phase 2a trial results, significantly reducing RSV viral load and symptoms while maintaining a favorable safety profile. EDP-323 offers potential as a... 
Via Benzinga
News headline image
Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV)
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals to Participate in Investor Conferences in September
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
ENTA Stock Earnings: Enanta Pharma Beats EPS, Beats Revenue for Q3 2024 ↗
ENTA stock results show that Enanta Pharma beat analyst estimates for earnings per share and beat on revenue for the third quarter of 2024. 
Via InvestorPlace
News headline image
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals to Participate at the JMP Securities Life Sciences Conference
From Enanta Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >